A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

November 29, 2016

Primary Completion Date

May 11, 2022

Study Completion Date

May 11, 2022

Conditions
Advanced Gastric Cancer
Interventions
BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

Ipilimumab

Specified dose on specified days

BIOLOGICAL

Relatlimab

Specified dose on specified days

BIOLOGICAL

BMS-986205

Specified dose on specified days

DRUG

Rucaparib

Specified dose on specified days

Trial Locations (35)

2031

Local Institution, Randwick

2145

Local Institution - 0035, Westmead

3084

Local Institution - 0033, Heidelberg

7000

Local Institution - 0041, Chur

8091

Local Institution - 0042, Zurich

10065

Local Institution - 0007, New York

15232

UPMC, Pittsburgh

19111

Local Institution - 0005, Philadelphia

20007

Local Institution - 0036, Washington D.C.

20133

IRCCS Istituto Nazionale Tumori Milano, Milan

20141

Local Institution - 0014, Milan

21224

Local Institution - 0006, Baltimore

32224

Local Institution - 0038, Jacksonville

32610

UF Health Medical Oncology - Davis Cancer Pavilion, Gainesville

52621

Local Institution, Ramat Gan

55905

Local Institution - 0017, Rochester

63110

Local Institution - 0003, St Louis

64239

Local Institution, Tel Aviv

69120

Local Institution - 0039, Heidelberg

80045

University Of Colorado, Aurora

85054

Mayo Clinic Arizona, Phoenix

97225

Local Institution - 0002, Portland

98109

Local Institution - 0004, Seattle

169610

Local Institution - 0050, Singapore

91010-3000

Local Institution - 0020, Duarte

06520

Local Institution - 0032, New Haven

07601

Local Institution - 0001, Hackensack

T6G 1Z2

Local Institution, Edmonton

V5Z 4E6

Local Institution, Vancouver

K1H 8L6

Local Institution, Ottawa

M4N 3M5

Local Institution - 0025, Toronto

M5G 2M9

Local Institution - 0021, Toronto

04103

Local Institution - 0043, Leipzig

1081 HV

Local Institution, Amsterdam

3584 CX

Local Institution, Utrecht

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT02935634 - A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter